- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
JCR Pharmaceuticals Co Ltd (4552)
JCR Pharmaceuticals Co Ltd stock price live, this page displays TYO 4552 stock exchange data. View the 4552 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the JCR Pharmaceuticals Co Ltd real time stock price chart below.
What Is the JCR Pharmaceuticals Co Ltd Stock Price Today?
The JCR Pharmaceuticals Co Ltd stock price today is 474.0.
What Is the Stock Symbol for JCR Pharmaceuticals Co Ltd?
The stock symbol for JCR Pharmaceuticals Co Ltd is "4552."
What Stock Exchange Does JCR Pharmaceuticals Co Ltd Trade On?
JCR Pharmaceuticals Co Ltd is listed and trades on the Tokyo stock exchange.
Is JCR Pharmaceuticals Co Ltd a Good Stock to Buy?
Determining whether JCR Pharmaceuticals Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4552 quote. (ISIN: JP3701000006)
What Is the JCR Pharmaceuticals Co Ltd Stock Price Today?
The JCR Pharmaceuticals Co Ltd stock price today is 474.0.
What Is the Stock Symbol for JCR Pharmaceuticals Co Ltd?
The stock symbol for JCR Pharmaceuticals Co Ltd is "4552."
What Stock Exchange Does JCR Pharmaceuticals Co Ltd Trade On?
JCR Pharmaceuticals Co Ltd is listed and trades on the Tokyo stock exchange.
Is JCR Pharmaceuticals Co Ltd a Good Stock to Buy?
Determining whether JCR Pharmaceuticals Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4552 quote. (ISIN: JP3701000006)
Tokyo
Currency in JPY
474.0
-5.0(-1.04%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
466.0
485.0
52 wk Range
444.0
824.0
High dividend Yield
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
466.0485.0
52 wk Range
444.0824.0
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(4.18%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(4.18%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
4552 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
600.0
Upside
+26.58%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
1 Buy
5 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 600.0
(+26.58% Upside)
Earnings
Latest Release
Jul 30, 2026
EPS / Forecast
-15.64 / --
Revenue / Forecast
9.7B / 10.4B
Compare 4552 to Peers and Sector
Metrics to compare | 4552 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4552PeersSector | |
|---|---|---|---|---|
P/E Ratio | 70.8x | 12.8x | −0.4x | |
PEG Ratio | 0.61 | 0.03 | 0.00 | |
Price/Book | 1.3x | 1.1x | 2.6x | |
Price / LTM Sales | 1.4x | 1.7x | 3.0x | |
Upside (Analyst Target) | 14.4% | 24.4% | 56.0% | |
Fair Value Upside | Unlock | 13.8% | 9.1% | Unlock |
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was founded in 1975 and is based in Ashiya, Japan.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the JCR Pharmaceuticals (4552) Stock Price Today?
The JCR Pharmaceuticals stock price today is 474.0 JPY.
What Stock Exchange Does JCR Pharmaceuticals Trade On?
JCR Pharmaceuticals is listed and trades on the Tokyo Stock Exchange.
What Is the Stock Symbol for JCR Pharmaceuticals?
The stock symbol for JCR Pharmaceuticals is "4552."
Does JCR Pharmaceuticals Pay Dividends? What’s The Current Dividend Yield?
The JCR Pharmaceuticals dividend yield is 4.18%.
What Is the JCR Pharmaceuticals Market Cap?
As of today, JCR Pharmaceuticals market cap is 58.45B JPY.
What Is JCR Pharmaceuticals's Earnings Per Share (TTM)?
The JCR Pharmaceuticals EPS (TTM) is 6.7.
When Is the Next JCR Pharmaceuticals Earnings Date?
JCR Pharmaceuticals will release its next earnings report on Oct 28, 2026.
From a Technical Analysis Perspective, Is 4552 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has JCR Pharmaceuticals Stock Split?
JCR Pharmaceuticals has split 1 times.
How Many Employees Does JCR Pharmaceuticals Have?
JCR Pharmaceuticals has 985 employees.
What is the current trading status of JCR Pharmaceuticals (4552)?
As of Aug 03, 2026, JCR Pharmaceuticals (4552) is trading at a price of 474.0 JPY, with a previous close of 479.0 JPY. The stock has fluctuated within a day range of 466.0 JPY to 485.0 JPY, while its 52-week range spans from 444.0 JPY to 824.0 JPY.
What Is JCR Pharmaceuticals (4552) Price Target According to Analysts?
The average 12-month price target for JCR Pharmaceuticals is 600.0 JPY, with a high estimate of 900 JPY and a low estimate of 430 JPY. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +26.58% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.